{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:53:24Z","timestamp":1781222004339,"version":"3.54.1"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"47","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,12,14]]},"DOI":"10.1093\/eurheartj\/ehu305","type":"journal-article","created":{"date-parts":[[2014,8,23]],"date-time":"2014-08-23T00:13:29Z","timestamp":1408752809000},"page":"3377-3385","source":"Crossref","is-referenced-by-count":168,"title":["Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial"],"prefix":"10.1093","volume":"35","author":[{"given":"G\u00fcnter","family":"Breithardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Berkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne S.","family":"Hellkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan P.","family":"Piccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna R.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliya","family":"Lokhnygina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manesh R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graeme J.","family":"Hankey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Hacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Nessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A. A.","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Califf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,8,22]]},"reference":[{"key":"key\n\t\t\t\t20170515130941_EHU305C1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ahj.2009.02.005","article-title":"Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran","volume":"157","year":"2009","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20170515130941_EHU305C2","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"RE-LY Steering Committee and Investigators","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130941_EHU305C3","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ahj.2009.08.026","article-title":"Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment","volume":"159","year":"2010","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20170515130941_EHU305C4","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"AVERROES Steering Committee and Investigators","year":"2011","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t20170515130941_EHU305C5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ahj.2009.11.025","article-title":"Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study","volume":"159","author":"ROCKET AF Study Investigators","year":"2010","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20170515130941_EHU305C6","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"ROCKET AF Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130941_EHU305C7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale","volume":"159","author":"ARISTOTLE Investigators","year":"2010","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20170515130941_EHU305C8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"ARISTOTLE Committees and Investigators","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130941_EHU305C9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2010.06.042","article-title":"Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)","volume":"160","year":"2010","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20170515130941_EHU305C10","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"the ENGAGE AF-TIMI 48 Investigators","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170515130941_EHU305C11","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.ahj.2005.06.026","article-title":"Rationale and design of ACTIVE: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events","volume":"151","author":"Active Steering Committee, ACTIVE Investigators","year":"2006","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20170515130941_EHU305C12","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with nonvalvular atrial fibrillation (SPORTIF III): randomised controlled trial","volume":"362","author":"Executive Steering Committee of the SPORTIF III Investigators","year":"2003","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170515130941_EHU305C13","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/europace\/eul097","article-title":"ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society","volume":"8","author":"American College of Cardiology; American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society","year":"2006","journal-title":"Europace"},{"key":"key\n\t\t\t\t20170515130941_EHU305C14","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"ESC Committee for Practice Guidelines (CPG)","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170515130941_EHU305C15","doi-asserted-by":"crossref","first-page":"82S","DOI":"10.1378\/chest.89.2_Supplement.82S","article-title":"Cerebral embolism","volume":"89","year":"1986","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170515130941_EHU305C16","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","article-title":"Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation","volume":"26","author":"European Heart Survey Investigators","year":"2005","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170515130941_EHU305C17","first-page":"423","article-title":"The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management","volume":"11","year":"2009","journal-title":"Europace"},{"key":"key\n\t\t\t\t20170515130941_EHU305C18","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00392-011-0320-5","article-title":"Management of atrial fibrillation by primary care physicians in Germany: baseline results of the ATRIUM registry","volume":"100","author":"ATRIUM Investigators","year":"2011","journal-title":"Clin Res Cardiol"},{"key":"key\n\t\t\t\t20170515130941_EHU305C19","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ijcard.2012.03.053","article-title":"Atrial fibrillation management, outcomes and predictors of stable disease in daily practice: prospective non-interventional study","volume":"167","year":"2013","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20170515130941_EHU305C20","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1161\/CIRCEP.112.970749","article-title":"Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry","volume":"5","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"key\n\t\t\t\t20170515130941_EHU305C21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/eut263","article-title":"Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboembolic events\u2014European Registry in Atrial Fibrillation (PREFER in AF)","volume":"16","year":"2014","journal-title":"Europace"},{"key":"key\n\t\t\t\t20170515130941_EHU305C22","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0003-4975(95)00887-X","article-title":"Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation","volume":"61","year":"1996","journal-title":"Ann Thorac Surg"},{"key":"key\n\t\t\t\t20170515130941_EHU305C23","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","year":"2010","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170515130941_EHU305C24","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","article-title":"Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal\/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs\/Alcohol Concomitantly) score","volume":"57","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170515130941_EHU305C25","article-title":"2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary","year":"2014","journal-title":"J Am College Cardiol"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/35\/47\/3377\/17050740\/ehu305.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,24]],"date-time":"2017-08-24T07:46:45Z","timestamp":1503560805000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-lookup\/doi\/10.1093\/eurheartj\/ehu305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,22]]},"references-count":25,"journal-issue":{"issue":"47","published-online":{"date-parts":[[2014,8,22]]},"published-print":{"date-parts":[[2014,12,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehu305","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,22]]}}}